In a series of open label sequential trials 36% of cancer patients with active disease (breast, lung, kidney, ovarian and prostate cancer) reported significant prolongation of life and/or remain alive and 32% reported statistically significant improvement (D. M. Morré and D. J. Morré. Catechin-vanilloid synergies with potential clinical applications in cancer. Rejuvenation Res. 9:45-55). Nearly all of the patients had received extensive chemo- and radiation therapy, yet the CAPSOL-T® was still of significant benefit.
|
